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ABSTRACT
Objective To assess the risk of attempted suicide before,
during,andaftertreatmentwithisotretinoinforsevereacne.
Design Retrospective cohort study linking a named
patient register of isotretinoin users (1980-9) to hospital
discharge and cause of death registers (1980-2001).
Setting Sweden, 1980-2001.
Population 5756 patients aged 15 to 49 years prescribed
isotretinoin for severe acne observed for 17197 person
years before, 2905 person years during, and 87120
person years after treatment.
Main outcome measures Standardised incidence ratio
(observednumberdividedbyexpectednumberofsuicide
attempts standardised by sex, age, and calendar year),
calculated up to three years before, during, and up to
15 years after end of treatment.
Results 128 patients were admitted to hospital for
attempted suicide. During the year before treatment, the
standardised incidence ratio for attempted suicide was
raised:1.57(95%confidenceinterval0.86to2.63)forall
(including repeat) attempts and 1.36 (0.65 to 2.50)
counting only first attempts. The standardised incidence
ratioduringanduptosixmonthsaftertreatmentwas1.78
(1.04 to 2.85) for all attempts and 1.93 (1.08 to 3.18) for
first attempts. Three years after treatment stopped, the
observed number of attempts was close to the expected
numberandremainedsoduringthe15yearsoffollow-up:
standardised incidence ratio 1.04 (0.74 to 1.43) for all
attemptsand0.97(0.64to1.40)forfirstattempts.Twelve
(38%) of 32 patients who made their first suicide attempt
before treatment made a new attempt or committed
suicide thereafter. In contrast, 10 (71%) of the 14 who
made their first suicide attempt within six months after
treatment stopped made a new attempt or committed
suicide during follow-up (two sample test of proportions,
P=0.034). The number needed to harm was 2300 new six
month treatments per year for one additional first suicide
attempt to occur and 5000 per year for one additional
repeat attempt.
Conclusions An increased risk of attempted suicide was
apparent up to six months after the end of treatment with
isotretinoin, which motivates a close monitoring of
patients for suicidal behaviour for up to a year after
treatment has ended. However, the risk of attempted
suicide was already rising before treatment, so an
additionalriskduetotheisotretinointreatmentcannotbe
established.Aspatientswithahistoryofsuicideattempts
before treatment made new attempts to a lesser extent
than did patients who started such behaviour in
connection with treatment, patients with severe acne
should not automatically have isotretinoin treatment
withheld because of a history of attempted suicide.
INTRODUCTION
Isotretinoin (13-cis-retinoic acid) has been used since
the 1980s to treat severe recalcitrant nodular acne
with good effect, but case reports and spontaneous
reporting of adverse drug reactions have suggested an
associationbetweenisotretinoin,depression,andsuici-
dal behaviour.
1-3 Observational studies have had con-
flicting results, however.
4-6 Because a causal relation
between isotretinoin and psychiatric reactions was dif-
ficulttoexclude,labellingchangesstrengtheningwarn-
ings about psychiatric adverse reactions have been
added in productinformation for isotretinoin products
within the EU despite contradictory evidence.
The association between acne, psychiatric morbid-
ity, and suicide attempts has been described,
7-11 and
some authors have observed that isotretinoin actually
leads to an improvement in anxiety and depression
because of the clearing of disfiguring acne.
12-16 Acne
in itself is not considered to be a serious condition. If
its treatment is suspected to entail severe side effects,
the harm-benefit balance of that treatment must be
thoroughly investigated. New data suggesting plausi-
ble biological mechanisms elucidating the association
betweenretinoid regulationand mood through mono-
aminergic systems have been emerging.
17
Ourunderlyinghypothesiswasthatpeoplewithsevere
acne may be at a higher risk of attempted suicide regard-
lessofexposuretoisotretinoin.Theaimofthisstudywas
to assess the risk of suicide attempts before, during, and
after treatment with isotretinoin for severe acne.
METHODS
Identification of study population
The study population consisted of patients prescribed
isotretinoin for severe acne between 1980 and 1990,
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Isotretinoin is not registered in Sweden, and it can be
dispensed only within a compassionate use pro-
gramme after special application to the Medical Pro-
ducts Agency. We identified the study population in
the register of named patients supplied the drug.
The individual application for a prescription holds
information on prescribed dosage and total quantity;
we used this to estimate the duration of treatment. We
usedthedateofgrantingtheprescriptionasaproxyfor
thefirstdateoftreatment.Weconsideredpatientstobe
exposed from the date of granting of the prescription
and for the number of days for which the prescribed
quantity at the prescribed dosage would suffice. For
applications for which information on dosage was
missing (197 patients, 3.4%), we used the sex specific
mediandailydose.For27prescriptions,thetotalquan-
titywasmissing;fortheseweusedthesexspecificmed-
ian quantity.
Startingin1986-7,somedermatologicalclinicscould
be granted a “clinic approval” to prescribe isotretinoin
without individual applications on condition that the
requirements for individual applications were met. We
identified patients prescribed isotretinoin with clinic
approval in two steps. Each clinic approval was stored
atagivensinglepharmacy.Weaskedthesepharmacies
to submit the lists of patients filling these prescriptions,
together with the quantity of isotretinoin dispensed.
However, these lists held only the names and dates of
birthofthepatients—theuniquepersonalidentification
numbers were not registered. We then sent the lists
obtained from the pharmacies to the clinics that had
received the clinic approval, and they provided infor-
mationonpersonalidentitynumberandonactualstart-
ingandstoppingdatesoftreatmentaswellasprescribed
daily dose. The exact duration of treatment was regis-
tered for 1441 (25%) of the 5756 patients in the cohort;
for the remaining population, we estimated it from the
prescribed amount and daily dose as stated in the indi-
vidual applications. We did sensitivity analyses on the
source of information (individual application versus
clinic approval) about exposure.
Identification and classification of suicide attempts and
deaths
We used the unique personal identification number to
link patients in the study population to the national
patient register of in-hospital care and to the cause of
death register, both maintained by the National Board
of Health and Welfare (www.socialstyrelsen.se). We
extracted hospital admissions for suicide attempts,
identified by codes for suicide attempt (ICD-8 (inter-
national classification of diseases, 8th revision) and
ICD-9 codes E950-E958; ICD-10 codes X60-X64)
and accidents with unclear intent (ICD-8 and ICD-9
codes E980-E988; ICD-10 codes Y10-Y34) entered
as “external cause,” as well as all deaths, with under-
lying causes, occurring between 1980 and 2001. We
did sensitivity analyses excluding accidents with
unclear intent.
We classified suicide attempts as occurring before,
during, or after treatment. We counted events that
occurred before treatment cumulatively for 12 month
periods backwards in time up to three years before
treatment. We restarted the cumulative counting of
eventsatthestartoftreatmentandcountedeventsdur-
ing the time of treatment, cumulatively for six months
thereafter, and then cumulatively in consecutive
12 month periods up to 15 years after treatment.
Time of observation and censoring
Thetotaltimeofobservationencompassed17197per-
son years of observation for up to three years before
treatment, 2905 person years during treatment, and
87120personyearsthereafter.Todistinguishbetween
ratesoffirsttimeandrepeatedsuicideattempts,wedid
two sets of analyses: for first attempts, we censored
patients at the first hospital admission for attempted
suicide, and they did not contribute person time of fol-
low-up after that. Patients who made a first suicide
attempt before treatment thus did not contribute any
exposed treatment time in the analyses. In contrast, in
theanalysisofthetotalnumberofsuicideattempts,any
patient who attempted suicide continued to contribute
person time after that event, and we counted subse-
quent hospital admissions. For both these analyses,
we censored patients at the time of death (for any
cause) or at the end of follow-up (31 December 2001).
We chose not to define a “time at risk” after the end
of treatment with isotretinoin. To identify any long
term effects of treatment, we distinguished only
between time on treatment and time thereafter.
External and internal comparisons of rates of suicide
attempts
We compared the rates of attempted suicide in the dif-
ferent time windows before, during, and after treat-
ment with those of the general population, by using
the national patient register of in-hospital care. We
used sex, age (in five year bands), and calendar year
specific rates in the general population to calculate
theexpectednumberofeventsinthestudypopulation,
specifically for each time window analysed, before,
during, and after treatment. In the study population,
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Fig 1 | Standardised incidence ratios for accumulated first suicide attempts and all attempts
from up to three years before (shaded area) to up to 15 years after treatment in all patients.
Thin lines show 95% confidence intervals
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estimating the expected number of events specifically
for sex, for age in five year bands, for calendar year,
and for time window. We then calculated the standar-
disedincidenceratioastheratiobetweentheobserved
number of cases and the expected number of cases.
We alsouseda cohort crossoveranalysisto makean
internal comparison within the treated population,
between rates of attempted suicide one year before
treatment with the highest observed rates during or
aftertreatment.
18Bycalculatingthedifferencebetween
these rates, we could estimate the absolute risk differ-
ence, assuming that the entire increase in risk was due
to the treatment. We then used these rates to calculate
the number needed to harm.
We thus made two overall comparisons. Firstly, we
compared the study cohort with the general popula-
tion, enabling an estimate of relative differences in
the occurrence of suicide attempts between the study
populationand the backgroundpopulation.Secondly,
an internal comparison within the study population
gave an estimate of the absolute differences in risk
before, during, and after treatment with isotretinoin
for severe acne.
Deaths by suicide
In a separate analysis, we analysed the rates of com-
pleted suicides. The expected number of suicides
came from mortality data for the entire general popu-
lation, and we calculated mortality rates, standardised
bysex,age(infiveyearbands),andcalendaryear.The
causes of death, for both the study population and the
general population, came from the national cause of
death register. We used Stata for statistical analyses.
RESULTS
The cohort comprised 5756 people, of whom 3613
(63%) were male. The mean age of male patients at
first prescription was 22.3 (SD 6.6) years, and that of
female patients was 27.1 (8.0) years. The mean length
of treatment was 6.0 (SD 4.0) months for male patients
and6.1(3.9)monthsforfemalepatients.Thetotaltime
of treatment was 1819 person years for male patients
and 1091 person years for female patients (table 1).
More than 90% of patients were prescribed only one
course of treatment.
Between 1980 and 2001, 128 (2.2%) patients were
discharged from in-hospital care at least once after a
suicide attempt, of whom 70 (1.9%) were male and 58
(2.7%)werefemale.Intotal,210dischargeswereregis-
tered (1.6 per person). Of the suicide attempts, 85%
were non-violent poisonings and overdoses (table 2).
Suicide attempts in isotretinoin cohort in relation to general
population
Between three years and one year before the start of
treatment, the standardised incidence ratios, compar-
ing the study cohort with the general population, gra-
dually rose from 0.89 (95% confidence interval 0.54 to
1.37)threeyearsbeforetreatmentto1.36(0.65to2.50)
inthe yearbeforetreatmentforfirstattemptsandfrom
0.99 (0.65 to 1.44) three years before treatment to 1.57
(0.86 to 2.63) in the year preceding treatment for all
attempts. The risks were highest within six months
after the start of treatment: 1.93 (1.08 to 3.18) for first
attempts and 1.78 (1.04 to 2.85) for all attempts. The
standardised incidence ratios then decreased, and the
numberofobservedattemptswasclosetotheexpected
number within three years after treatment: standar-
dised incidence ratio 0.97 (0.64 to 1.40) for first
attempts and 1.04 (0.74 to 1.43) for all attempts (fig 1).
Eight years after treatment, the standardised inci-
dence ratio for all attempts started to rise slightly
above one, but this only occurred for female patients.
Whereasthestandardisedincidenceratiosforbothfirst
and repeat events were close to or below one for male
patients (fig 2), those for repeat events in female
patients (fig 3) were significantly raised 11 years after
treatment(1.36,1.06to1.70).Wesawnosuchincrease
for first attempts in female patients.
Table 1 |Patients’ demographics and treatment characteristics.
Values are numbers (percentages) unless stated otherwise
Characteristics
Males
(n=3613)
Females
(n=2143)
Age (years) at first prescription:
Mean (SD) 22.3 (6.6) 27.1 (8.0)
Median (interquartile range) 20 (18-25) 26 (21-33)
Prescribed daily doses (mg):
Mean (SD) 44.5 (15.7) 39.2 (13.1)
Median (interquartile range) 40 (30-60) 40 (30-50)
Missing 129 (3.6) 68 (3.2)
Duration of treatment (months):
Mean (SD) 6.0 (4.0) 6.1 (3.9)
Median (interquartile range) 5.0 (3.9-6.6) 4.9 (4.0-6.6)
TotalNoofpersonyearsontreatment 1819 1091
No of treatment courses:
1 3320 (91.9) 1956 (91.3)
2 272 (7.5) 175 (8.2)
3 19 (0.5) 10 (0.5)
4 2 (0.1) 2 (0.1)
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Fig 2 | Standardised incidence ratios for accumulated first suicide attempts and all attempts
from up to three years before (shaded area) to up to 15 years after treatment in male patients.
Thin lines show 95% confidence intervals
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scribeddailydosesordurationoftreatmentbetweenpeo-
ple who attempted suicide and the cohort as a whole
(table 3).However,the14femalepatientswhoattempted
suicide after treatment had received two or more treat-
ment courses significantly more often (24%, 95% confi-
dence interval 13% to 35%) than had the female patients
never admitted for attempted suicide (9%, 8% to 10%)
(P<0.001, two sample test of proportions).
Patients who made their first suicide attempt before
treatment (n=32) did not seem to have their suicidal
behaviour reinforced during or after treatment: 12
(38%,21%to54%)ofthesepatientsmadenewattempts
orcommittedsuicideduringthefollow-up.Incontrast,
among the 14 who made a first suicide attempt during
treatment or within six months after the end of
treatment, 10 (71%, 48% to 95%) made a new attempt
or committed suicide during follow-up (P=0.034, two
sample test of proportions).
Suicide attempts—comparisons within isotretinoin cohort
Aswesawwhencomparingthecohortwiththegeneral
population, the rates of attempted suicide per person
years of follow-up rose from three years before treat-
ment and through to the actual treatment when we
made internal comparisons within the treated cohort
(fig4).Thehighestratedifferencewasforfirstattempts:
0.86 (95% confidence interval −0.78 to 2.50) cases per
1000 person years, comparing the rate during the year
before treatment (1.66/1000 person years) with the
rate within six months after treatment (2.52/1000 per-
sonyears).Forallattempts,thecorrespondingratedif-
ferencewas0.40(−1.46to2.26)per1000personyears.
These rate differences yielded a number needed to
harm of 2300 new six month treatments per year for
one additional first suicide attempt to occur and 5000
per year for one additional repeat attempt, assuming
that the entire additional risk could be attributed to
the treatment. For both first and repeated suicide
attempts, the rates and rate differences were higher for
female patients than for male patients (fig 5 and fig 6).
Death by suicide
Seventeen male patients and seven female patients
committed suicide by the end of 2001 (0.4%). One
man committed suicide during treatment and two
within one year after treatment. The first woman who
committed suicide did so six years after treatment.
Of the suicides, 42% were non-violent poisonings
and overdoses (table 2) and 13 (54%) of the patients
Table 2 |Details of suicide attempts and completed suicides by sex and by timing of events in relation to treatment
Ever before treatment During treatment plus 1 year >1-15 years after treatment
Males Females Males Females Males Females
Suicide attempts
No of patients 15 17 11 9 44 32
Age (years) at first event:
Mean 23.2 26.0 25.6 27.4 32.3 33.7
Median (interquartile range) 22 (19-25) 27 (19-33) 24 (19-29) 26 (19-35) 32 (27-36) 33 (28-39)
Range 15-44 15-38 18-43 17-42 18-48 19-49
Method*:
Non-violent 12 14 9 8 38 28
Violent 3 3 3 1 5 4
Completed suicides
No of patients NA NA 3 0 14 7
Age (years) at suicide:
Mean NA NA 32.7 NA 33.5 35.6
Median (interquartile range) NA NA 23; 37; 38† NA 32 (29-41) 37 (31-40)
Range NA NA 23-38 NA 21-46 25-45
Method*:
Non-violent NA NA 1 NA 8 1
Violent NA NA 2 NA 6 6
NA=not applicable.
*Non-violent=poisoning, overdose; violent=cut/stab, jump, drowning, gas, firearm, suffocation.
†Actual ages of three patients who committed suicide.
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cide.Thestandardisedmortalityratioformalepatients
whocommittedsuicide withinone yearaftertreatment
(n=3) was 1.9 (0.4 to 5.4). Within two years after treat-
ment, the standardised mortality ratios for suicide
among male patients went down to around one—that
is, the observed number was close to the expected—
andremainedtherethroughouttheobservationperiod
(data not shown). The highest standardised mortality
ratio for female patients occurred within 11 years after
treatment:sixsuicidesyieldedaratioof1.8(0.7to3.9).
Sensitivity analyses
We calculated separate incidences depending on the
source of information about exposure. We made one
estimationforpatientswithdurationsoftreatmentesti-
mated from dosage and quantity stated in the applica-
tionsforprescriptionsandoneforpatientswithknown
durations of treatments obtained from the clinics. The
patterns of incidences before, during, and after treat-
ment were identical, and the point estimates were
very similar. We found no differences in the patterns
ofincidenceswhenweexcludedaccidentswithunclear
intent.
DISCUSSION
Thisretrospectivecohortstudyof5756patientstreated
with isotretinoin for severe acne encompasses more
than 17000 person years of observation before treat-
ment,2900personyearsontreatment,and87000per-
son years of follow-up thereafter. During the
observationperiod,128patientswereadmittedtohos-
pital for attempted suicide on 210 occasions; 24
patients committed suicide. The data support our
hypothesis that severe acne, regardless of exposure to
isotretinoin, carries an increased risk of attempted sui-
cide.Thepointestimatesofthestandardisedincidence
ratiosrosegraduallyfromthreeyearsbeforetreatment
through to the year immediately before treatment.
However, none of these point estimates was statisti-
cally significant. The risk was significantly raised only
six months after the end of treatment. Two to three
years after treatment, the observed number of suicide
attempts was close to the expected number, given the
background rate in the population.
One condition for prescription of isotretinoin being
allowed was that the patient had been treated with tet-
racyclines for at least six months without improve-
ment. The increasing risk of attempted suicide during
the year before treatment with isotretinoin coincides
with the presumed treatment with tetracyclines. We
are not aware, however, of any hypotheses or signals
associating tetracycline with psychiatric side effects,
including suicide attempts.
Considering the increasing risk of attempted suicide
during the years before treatment, we cannot state
whether the continued rise during and immediately
after treatment was due to the natural course of severe
acneortonegativeeffectsofthe treatment.Asthestan-
dardised incidence ratio went down to one within two
to three years after treatment, a successful treatment
could—at the population level—have actually attenu-
ated the suicidal behaviour due to severe acne. Some
ofthepatients,possiblyvulnerabletoisotretinoin,who
madetheirfirstsuicideattemptincloserelationtotreat-
ment, may have done so as a consequence of exposure
to the drug.However, patientswithout a positiveeffect
of treatment might have despaired at the prospect of
continuing to live with disfiguring acne. Furthermore,
we cannot exclude the possibility that patients whose
acne improved after treatment were distraught if no
improvement in their social life followed the physical
improvement. We must stress that we cannot exclude
the possibility that the raised risk of suicide attempts
during treatment and six months after treatment is
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Table 3 |Prescribed daily doses, duration of treatment, and number of treatment courses:
total study population and patients admitted to hospital for suicide attempt, by sex. Values
are numbers (percentages) unless stated otherwise
Males Females
Prescribed daily dose (mean (SD) mg)
All 44.5 (15.7) 39.2 (13.1)
Suicide attempt, treatment + 12 months 35.0 40.0
Suicide attempt, treatment + 15 years 43.4 38.1
Suicide attempt, more than once 39.4 38.4
Length of treatment (mean (SD) days)
All 183.9 (122.4) 185.9 (120.0)
Suicide attempt, treatment + 12 months 200.3 222.9
Suicide attempt, treatment + 15 years 201.5 204.6
Suicide attempt, more than once 188.6 240.0
No of treatment courses
All:
1 3320 (91.9) 1956 (91.3)
2 272 (7.5) 175 (8.2)
3 19 (0.5) 10 (0.5)
4 2 (0.1) 2 (0.1)
Suicide attempt, treatment + 15 years:
1 6 3( 9 0 ) 4 4( 7 6 )
2 5 (7) 13 (22)
3 2 (3) 1 (2)
40 0
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probable interpretation is that the underlying severe
acne may best explain the raised risk.
Although we do not know if some patients in the
study population were also treated with isotretinoin
after 1990, we could detect no long term effects of the
treatment on the risk of patients starting suicidal beha-
viour. However, the standardised incidence ratio for
repeated attempts increased among female patients
eight years after treatment. Whether this is due to
new episodes of treatment or to the presumed higher
psychiatric vulnerability of women to severe acne is
unknown.
19
Patients who made suicide attempts before treat-
ment did not seem to have this behaviour reinforced
by treatment with isotretinoin. Patients with acne who
made their first suicide attempt in connection with iso-
tretinoin treatmentmade new attemptsapproximately
twice as often as did those who made their first suicide
attempt before the exposure to isotretinoin. One pos-
sible explanation for this difference may be that
patients with an assumed acne induced suicidality
had an improvement in their severe acne after a suc-
cessful treatment. In those patients who made a first
suicide attempt during or soon after the treatment,
this behaviour could be a side effect of the treatment
itselforaconsequenceoftreatmentfailureoroflackof
perceptionofimprovingquality oflifedespitesuccess-
ful treatment. A finding in line with this is that women
whomadesuicideattemptsreceivedtwoorthreetreat-
ments more often than did women who did not make
suicide attempts. This indicates treatment failure as a
possible explanation for suicidal behaviour. This may
indicatethatahistoryofsuicideattemptsneednotbea
decisivefactorwhenconsideringtreatmentwithisotre-
tinoin.
Attemptedsuicideis,however,anuncommonevent.
In the internal comparison of the cohort, the number
needed to harm was 2300 per year for one additional
first suicide attempt and 5000 per year for one addi-
tionalrepeatattempttooccur,assumingthattheentire
increase in risk was due to treatment. A physician
would thus need to start treatments in more than
2000 new patients during one year to see one addi-
tional suicide attempt due to treatment. Nevertheless,
the most important proactive measure to be taken
would be to closely monitor all patients’ psychiatric
status, not only during treatment but also for at least a
year after treatment with isotretinoin.
Comparisons with previous studies and findings
Many case reports and case series have reported ser-
ious adverse psychiatric events associated with isotre-
tinoin treatment.
20 In epidemiological studies, the
results have been conflicting. No association was
found between isotretinoin treatment and depression,
psychotic symptoms, suicide, or suicide attempts in a
cohort of more than 7000 isotretinoin users.
4 On the
other hand, a significant relative risk of 2.68 (95% con-
fidenceinterval1.10 to6.48) wasfound in126 patients
with incident depression and acne in a case crossover
study.
6 Furthermore, 1419 army conscripts treated
with isotretinoin for acne were found to use mental
health services more than did a control group with
psoriasis.
5
In several prospective studies, treatment with iso-
tretinoin has been shown to improve patients with
acne emotionally and psychologically.
12-17 However,
these studies were probably too small to detect nega-
tiveeventswithincidencesintheorderof1-2per1000
person years. Many studies have shown that acne in
itself has a negative psychological impact.
7-11 For
example, in line with our findings, severe acne has
been shown to be associated with suicidal
behaviour.
10
The standardised incidence ratios and rates of
attempted suicide were higher in female than in male
patients; a stronger emotional impact of acne in girls
hasalsobeenobservedpreviously.
19Wealsoobserved
thatwomenwhomadesuicideattemptsaftertreatment
had more often received two or more treatment
courses with isotretinoin than had women who did
not make suicide attempts. This indicates that they
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suicide attempts and all attempts from up to three years
before and up to two years after treatment for female patients
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that the emotional impact of severe acne may be more
pronounced in female patients.
Several studies have shown that the molecular com-
ponents needed for retinoic acid signalling are
expressed in the adult brain, suggesting that retinoids
could play a role in affective disorders.
21-29 In young
adult mice, chronic administration of isotretinoin
induced depression related behaviours.
22 These
changes were not seen in adult rats.
27 In 13 humans,
isotretinoin decreased orbitofrontal cortex meta-
bolism, but this decrease was not accompanied by an
increase in the severity of depression.
28
Limitations and strengths of study
Ourstudyhassomelimitations.Despitethelargenum-
ber of person years of exposure and follow-up, the sta-
tistical precision was low. The standardised incidence
ratios were clearly rising before treatment, but we
found no statistical significance until six months after
treatment. In the internal cohort crossover analysis—
that is, analysing outcomes before and after treatment
in the same population—the differences in incidence
did not reach statistical significance, making the
estimated number needed to harm uncertain. We esti-
mated the exposure to isotretinoin from prescriptions,
not from actual use. However, during the 1980s, iso-
tretinoin was a newly available drug for the treatment
of severe acne. One requirement for prescribing the
drug was that the patient had been treated with anti-
biotics for at least six months without improvement.
This would have made this population motivated for
treatment, and thus likely to have complied with it.
After 1986-7, dermatology clinics could prescribe
isotretinoin without an individual application for
each patient. We could not collect the identities of all
patients treated at such clinics. These unidentified
patients would, however, be a source of bias only if
the frequency/pattern of suicide attempts can be
assumedto be distinctly different in that “lost”popula-
tion. We cannot conceive of a mechanism to justify
such an assumption.
We had no information on the effect of treatment. A
bias would exist if the patients who made suicide
attempts had a poorer effect of treatment than did
those who did not make such attempts. In that case,
thesuicidalbehaviourshouldbeattributedtothetreat-
mentresistantacneandnottothetreatment.However,
such bias would only strengthen the assumed associa-
tion between severe acne and suicidal behaviour.
Loss to follow-up is a minor source of error, as only
people who emigrated from Sweden were truly lost to
follow-up. A bias would result if patients treated with
isotretinoin emigrated and made a suicide attempt
thereafter. This would most probably lead to our
observed standardised incidence ratio being under-
estimated.
No potential confounding factors other than age,
sex, and calendar year were available for analysis.
The cohort crossoveranalysis none the less attenuated
theeffectfromunmeasuredconfoundingfactors,aswe
compared the exposed population with itself before
treatment. On the other hand, we could not account
or control for effects of risk factors changing within a
person over time. For example, evidence exists of an
association between unemployment and attempted
suicide,aswellasbetweendivorceandsuicide/suicidal
behaviour.
30-32 As regards the external comparison
with the general population, our risk estimates would
be overestimated if the rates of unemployment or
separation were higher in the exposed population. In
the internal comparison of rates before, during, and
aftertreatment,thepopulationagedovertime.Separa-
tions and divorces may well have been increasingwith
age in the cohort. The rising rates of attempted suicide
before and immediately after treatment would then
have been overestimated as a result of this bias. How-
ever, in the period after treatment, the decline in these
rates would have been underestimated if the rates of
separations continued to rise with time. We consider
that any unmeasured confounder changing intra-
individually over time would have to correlate with
the increasing severity of acne, as well as with treat-
ment and its end, to explain the observed results.
Such strong correlations are difficult to imagine.
In this study, we had data only on serious suicide
attempts leading to admission to hospital. Although
including such serious attempts can be considered a
strength, the fact that we could not include patients
who made less severe suicide attempts and who were
treated as outpatients, or who were not in contact at all
with health services, is also a possible limitation. This
would, however, mean that we have underestimated
the incidence of attempted suicide in our study, possi-
bly to a greater extent before treatment than during
and after treatment. Undocumented suicide attempts
may have occurred more often before treatment than
during and after treatment, as treatment with isotreti-
noin required an established contact with specialised
healthcare services, and this may have made such
patients more willing to seek medical help for suicidal
ideation or attempted suicide.
We used the same register to identify the suicide
attempts within the cohort that we used to calculate
the expected number of events. No bias in identifica-
tion of cases depending on exposure is thus probable.
Furthermore, this cohort should be close to represent-
ing 100% of the treated population in Sweden up to
1986, and a high proportion thereafter, and it was fol-
lowedfor upto15 years aftertreatment.Thetwocom-
parisons—with the general population and internally
within the cohort—gave the same results regarding
the pattern of incidence of suicide attempts. The ana-
lyses of standardised incidence ratios and rates before
treatment both confirm the existence, and give an esti-
mation of the extent, of the usually so elusive “con-
founding by indication.”
Conclusions and implications
Severe acne is not a trivial condition; in the absence of
treatment with isotretinoin, it is associated with an
increased risk of attempted suicide. At the level of the
RESEARCH
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tretinoinmayattenuatesuicidalbehaviour.Forcertain
vulnerable patients, however, isotretinoin may trigger
such behaviour.
The challenge for future studies is to find out how to
identifypeople whomaybe vulnerableto isotretinoin.
Physicians prescribing isotretinoin should be aware
that a history of psychiatric problems such as suicide
attempts need not constitute a decisive factor when
considering treatment with isotretinoin. Much more
important is the fact that suicide attempts can occur
quite a long time after treatment has stopped. For this
reason, close monitoring of the mental status of
patients receiving isotretinoin, as well as those with
severe acne, should be a part of the treatment process
and should continue for at least a year after the end of
treatment.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Case reports and spontaneous reports of adverse drug reactions have suggested an
associationbetweenisotretinoinandsuicidalbehaviour,but observationalstudies havehad
conflicting results
Isotretinoin has been shown to have behavioural effects in mice and effects on cerebral
metabolism in humans
WHAT THIS STUDY ADDS
Severe acne is a risk factor for attempted suicide; an additional risk may be present during
and up to one year after treatment with isotretinoin
Suicidal behaviour triggered during isotretinoin treatment more often leads to repeated
attempts or suicide than in patients with a history of suicide attempts before treatment
A history of attempted suicide may not need to be a contraindication when considering
treatment with isotretinoin
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